

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KELUN-BIOTECH**  
**科伦博泰**

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**

**四川科倫博泰生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6990)**

**VOLUNTARY ANNOUNCEMENT  
INCLUSION IN STOCK LIST OF  
STOCK CONNECT SOUTHBOUND TRADING LINK**

This announcement is made by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that pursuant to the Notice of Adjustment of Stock List of Southbound Trading Link of the Shanghai-Hong Kong Stock Connect (《關於滬港通下港股通標的調整的通知》) made by the Shanghai Stock Exchange on March 1, 2024, the Company will be included in the list of eligible shares of the Southbound Trading Link of the Shanghai-Hong Kong Stock Connect with effect from March 4, 2024.

The Board is of the view that the selection and inclusion of the Company in the list of eligible shares of the Shanghai-Hong Kong Stock Connect will facilitate the expansion of the Company’s shareholder base and help increase the trading liquidity of the shares of the Company.

By order of the Board

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**

**LIU Gexin**

*Chairman of the Board and Non-executive Director*

Hong Kong, March 3, 2024

*As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou and Dr. WANG Jingyi as executive Directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.*